KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Relationship Between Best Tumor Shrinkage and Progression-Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu-DOTA-TATE: Ad Hoc Analysis of the Phase III NETTER-1 Trial.

Marianne Pavel, Martyn E Caplin, Philippe Ruszniewski, Marianna Hertelendi, Eric P Krenning, Jonathan R Strosberg, NETTER‐1 Study Group

Cancer Med 14(9) e70744

PMID40272146
PMCIDPMC12020026
DOI10.1002/cam4.70744
发表日期2025-04-24
入排依据:The record is a subgroup/ad hoc analysis from the Phase III NETTER-1 trial. While it meets most eligibility criteria (oncology, human, randomized, Phase III, drug intervention, time-to-event endpoints), it is not an original formal-result report of the main trial, which is required for inclusion. It is a secondary analysis focusing on tumor shrinkage as a predictor, not the primary or key secondary efficacy result report.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:瀑布图;FIGURE 2:森林图/亚组分析图;FIGURE 3:非 KM 图;FIGURE 4:非 KM 图。
摘要

摘要

BACKGROUND: In many solid tumors, early tumor shrinkage predicts the durability of treatment response. It is unclear whether this is the case for neuroendocrine tumors treated with peptide receptor radionuclide therapy (PRRT). METHODS: Data from the phase III NETTER-1 study of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) for the treatment of advanced, well-differentiated, midgut NETs were used to investigate whether objective tumor shrinkage (local review) with 177Lu-DOTATATE is associated with progression-free survival (PFS) and overall survival (OS) duration. RESULTS: Overall, 117 patients were treated with 177Lu-DOTATATE (four cycles of 7.4 GBq every 8 weeks). In a landmark analysis, best tumor shrinkage from baseline until data cut-off (prior to first progression) was not associated with PFS (n = 102; hazard ratio: 1.002 [95% confidence interval (CI): 0.99-1.02]; nominal p = 0.7808). In further ad hoc analyses, patients on the 177Lu-DOTATATE arm were dichotomized into ≥ 30% tumor shrinkage from baseline (18/117 [15.4%]) and < 30% shrinkage (99/117 [84.6%]). Median (95% CI) PFS was 17.6 (16.5-30.3) months in the ≥ 30% shrinkage group and 25.0 (19.4-31.0) months in the < 30% group. OS was not significantly different for the two tumor shrinkage groups (not estimable [31.0 months-not estimable] and 44.3 [34.9-53.8] months, respectively). CONCLUSIONS: These results suggest the benefit of PRRT and the potential PFS and OS benefit of 177Lu-DOTATATE should not be based on tumor shrinkage (objective response versus stable disease) and that lack of tumor shrinkage should not impact application of the approved four cycles of 177Lu-DOTATATE.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Waterfall plot of best tumor shrinkage (local review) from baseline for (A) 177 Lu‐DOTATATE group ( n = 102) and (B) control group ( n = 86) (full analysis set). Seven patients in the control group had at least a 30% tumor reduction, but only four of these were considered a partial response due to censoring, progression of non‐target lesions, and progression at a later time point.
非 KM Figure
FIGURE 2Forest plot showing the impact of a one‐unit increase in best tumor shrinkage on the hazard rate for PFS by time point (full analysis set). Best tumor shrinkage was calculated based on the best percentage change from baseline in the sum of target lesion diameters (based on local scan assessment) until each of the time points and on or before first progression. PFS was determined from the relevant time point to first disease progression or death from any cause. An HR < 1.0 suggests a one‐unit increase in best tumor shrinkage may be associated with a decreased hazard rate for PFS (i.e., prolonged PFS), while an HR > 1.0 suggests a one‐unit increase in best tumor shrinkage may be associated with an increased hazard rate for PFS (i.e., reduced PFS). Control: High‐dose octreotide LAR 60 mg every 4 weeks. CI, confidence interval; HR, hazard ratio; LAR, long‐acting repeatable; PFS, progression‐free survival.
非 KM Figure
FIGURE 3Kaplan–Meier of PFS by tumor shrinkage (local review) up to study cut‐off for 177 Lu‐DOTATATE group ( n = 117) (full analysis set). CI, confidence interval; PFS, progression‐free survival.
非 KM Figure
FIGURE 4Kaplan–Meier of OS by tumor shrinkage (local review) up to study cut‐off for 177 Lu‐DOTATATE group ( n = 117) (full analysis set). CI, confidence interval; NE, not estimable; OS, overall survival.
非 KM Figure